COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Outpatient Registry Trial of Respiratory Tract Infections in Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00245453
Recruitment Status : Withdrawn (Terminated by sponsor)
First Posted : October 28, 2005
Last Update Posted : July 28, 2015
Information provided by:
CPL Associates

Brief Summary:
To measure the speed of bacterial eradication from the respiratory tract after administration of azithromycin or telithromycin.

Condition or disease Intervention/treatment Phase
Pneumonia, Bacterial Bronchitis, Chronic Drug: azithromycin Drug: telithromycin Drug: Clarythromycin Phase 4

Detailed Description:
To Evaluate the relationship between rate of S. pneumoniae killing in sputum, PK/PD, and clinical response of oral telithromycin and azithromycin in patients with AECB or CAP and to determine if there is a difference in the rates of infection site bacterial killing (as described above) between these 3 antibiotics against penicillin- and erythromycin-resistant S.pneumoniae

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized Aseptic Pharmacokinetic Pharmacodynamic Outpatient Registry Trial of Respiratory Tract Infections in Adults (RAPPORT)
Study Start Date : October 2005
Actual Study Completion Date : July 2006

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: 1 Azithromycin Drug: azithromycin
250 mg tablets; 2 tablets on day 1 (500 mg load) and 1 tablet QD on days 2-5

Active Comparator: 2 Clarythromycin Drug: Clarythromycin
500 mg extended release tablets; 2 tablets QD for 7 days

Active Comparator: 3 Telithromycin Drug: telithromycin
400 mg tablets; 2 tablets once daily (QD) for 5 days

Primary Outcome Measures :
  1. Time to bacterial eradication [ Time Frame: 11-18 days ]
  2. Bacteriologic outcome [ Time Frame: 11-18 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adult patients, either males or non-pregnant females, aged 18 to 75 years of age with clinical findings of CAP or AECB who are amenable to serial nasopharyngeal and oropharyngeal sampling and having positive Binax-NOW tests indicating infection with Streptococcus pneumoniae
  • Patients with a medical history and clinical findings consistent with a respiratory tract infection. A patient with advanced COPD, repeated exacerbations by history, a BINAX-NOW test consistent with S. pneumoniae and/or proven culture positivity for S. pneumoniae may be enrolled
  • All patients (CAP or AECB) must produce purulent sputum and be positive on the Urinary BINAX-NOW assay.
  • The female patient of child bearing potential must agree to use an accepted method of contraception (i.e., oral or implanted contraceptive with a barrier method, spermicide and barrier methods, or IUD). The patient must agree to continue with the same method throughout the study.

Exclusion Criteria:

  • Baseline sputum cultures known to be negative for S. pneumoniae, or negative urinary BINAX-NOW.
  • Patients with a microbiologically documented pathogen known prior to inclusion to be resistant to any of the study medications.
  • History of hypersensitivity to macrolides, azalides, ketolide antibiotics or history of serious hypersensitivity reaction to any drug.
  • Pre-existing impaired hepatic function or impaired renal function CCL <20ml/min
  • Patients who will require on-study treatment with medications known to have contraindicated drug interactions with telithromycin
  • Treatment with more than one dose of an antimicrobial prior to entry into the study

Others as per protocol

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00245453

Layout table for location information
United States, Kentucky
Western Kentucky Pulmonary Clinic
Louisville, Kentucky, United States, 42240
United States, Louisiana
Northshore Research Associates
Slidell, Louisiana, United States, 70461
Sponsors and Collaborators
CPL Associates
Layout table for investigator information
Principal Investigator: Jerome J Schentag, Pharm.D. State University of New York at Buffalo
Study Director: Joseph Paladino, Pharm.D. State University of New York at Buffalo
Additional Information:
Layout table for additonal information Identifier: NCT00245453    
Other Study ID Numbers: HMR3647A6004
First Posted: October 28, 2005    Key Record Dates
Last Update Posted: July 28, 2015
Last Verified: July 2015
Keywords provided by CPL Associates:
Additional relevant MeSH terms:
Layout table for MeSH terms
Respiratory Tract Infections
Pneumonia, Bacterial
Bronchitis, Chronic
Lung Diseases
Respiratory Tract Diseases
Bronchial Diseases
Lung Diseases, Obstructive
Bacterial Infections
Pulmonary Disease, Chronic Obstructive
Anti-Bacterial Agents
Anti-Infective Agents
Protein Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cytochrome P-450 CYP3A Inhibitors
Cytochrome P-450 Enzyme Inhibitors